Phenibut has a positive effect on metabolic processes in the nerve cells of the brain. Phenibut active substance (γ-β-amino-phenylbutyric acid hydrochloride) can be regarded as a derivative of γ-amino butyric acid (GABA) derivative or β-phenylethylamine. Phenibut possesses nootropic activity, and as a derivative of GABA has anxiolytic (tranquilizing) action. No effect on choline and adrenergic receptors.
The drug reduces tension, anxiety, fear, and improves sleep, so it is used for the treatment of neuroses and before operations. Phenibut lengthens and strengthens the effects of sleeping pills, narcotic, neuroleptic and antiparkinsonian agents. Phenibut devoid of anticonvulsant activity. Phenibut extend the latency period of nystagmus and shortens its duration and severity. The drug significantly reduces the symptoms of fatigue and vasovegetative symptoms, including headache, a feeling of heaviness in the head, sleep disturbances, irritability, emotional lability, and improves mental performance. Psychological performance (attention, memory, speed and accuracy of sensory-motor reactions) under the influence of phenibut improved, unlike the influence of tranquilizers. In patients with asthenia and emotionally labile patients from the first days of therapy improved subjective well-being, increased interest and initiative, motivation activities without undue sedation or excitation.
Absorption – high penetrates well in all body tissues and the blood brain barrier (about 0.1% to penetrate the brain tissue of the administered dose of the drug, and in young and elderly patients are much more). Evenly distributed in the liver and kidneys. It is metabolized in the liver – 80-95%, the pharmacologically inactive metabolites. Not accumulates. After 3 hours, the kidney begins to stand out. Approximately 5% is excreted by the kidneys unchanged, partly – with bile.
Asthenic and anxious-neurotic states: anxiety, fear, anxiety.
Elderly patients – sleep disorders, restless night’s sleep.
Prevention of anxiety disorders that arise before surgery and painful diagnostic studies.
Meniere’s disease; dizziness associated with dysfunction of the vestibular apparatus of various origins; Prevention of motion sickness when kinetoses (a condition that is characterized by nausea, vomiting, dizziness, and vestibular disorders caused by being in a moving object).
Children – treatment of stuttering, tics.
As an adjuvant in treatment of alcohol withdrawal syndrome.
Dosing and dosing regimen
Inside, after a meal.
Adults appoint 250-500 mg 3 times a day.
The maximum single dose in adults – 750 mg in patients over 60 years – 500 mg.
The course of treatment – 2-3 weeks. If necessary, the course may be extended for up to 4-6 weeks. Duration of treatment is determined by a physician taking into account the characteristics of the disease, drug tolerability and impact.
Children aged 8 to 14 years – 250 mg 3 times a day. Children older than 14 years are designated adult dose.
For treatment of alcohol withdrawal syndrome in the first days of treatment – at 250-500 mg 3 times a day and 750 mg – at night, with a gradual decrease in the daily dose to normal adult.
When disease and Meniere’s syndrome exacerbation period – 750 mg 3 times a day for 5-7 days, while reducing the severity of vestibular disorders – 250-500 mg 3 times a day for 5-7 days and then – 250 mg 1 times a day for 5 days. In less severe conditions – 250 mg 2 times a day for 5-7 days, followed by reduction of the dose to 250 mg 1 time per day for 7-10 days.
For the treatment of vertigo with vestibular dysfunction analyzer vascular and traumatic genesis – 250 mg 3 times daily for 12 days.